| Dr Harry G Hunt, MD | |
|
1212 Broad St, Columbia, MS 39429-3114 | |
| (601) 444-9266 | |
| (601) 444-9267 |
| Full Name | Dr Harry G Hunt |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 30 Years |
| Location | 1212 Broad St, Columbia, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346268786 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 15726 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwest Mississippi Medical Center | Clarksdale, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Delta Health System | 5890101208 | 7 |
News Archive
Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.
"Traction was introduced before it was properly evaluated in high-quality randomized trials, and as an intervention is already part of usual practice," said lead author Judy M.A. Clarke, M.D. "It is hard to convince health care providers not to use it."
In a paper to be published Nov. 22 in the online edition of the journal Science, a team of University of Wisconsin-Madison researchers reports the genetic reprogramming of human skin cells to create cells indistinguishable from embryonic stem cells.
Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.
› Verified 5 days ago
| Entity Name | Anazia Medical, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245348499 PECOS PAC ID: 9133013659 Enrollment ID: O20040213000289 |
News Archive
Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.
"Traction was introduced before it was properly evaluated in high-quality randomized trials, and as an intervention is already part of usual practice," said lead author Judy M.A. Clarke, M.D. "It is hard to convince health care providers not to use it."
In a paper to be published Nov. 22 in the online edition of the journal Science, a team of University of Wisconsin-Madison researchers reports the genetic reprogramming of human skin cells to create cells indistinguishable from embryonic stem cells.
Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.
› Verified 5 days ago
| Entity Name | Jefferson County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043204555 PECOS PAC ID: 5496657876 Enrollment ID: O20040227000452 |
News Archive
Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.
"Traction was introduced before it was properly evaluated in high-quality randomized trials, and as an intervention is already part of usual practice," said lead author Judy M.A. Clarke, M.D. "It is hard to convince health care providers not to use it."
In a paper to be published Nov. 22 in the online edition of the journal Science, a team of University of Wisconsin-Madison researchers reports the genetic reprogramming of human skin cells to create cells indistinguishable from embryonic stem cells.
Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.
› Verified 5 days ago
| Entity Name | Anazia Medical Ii, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174627459 PECOS PAC ID: 4688644321 Enrollment ID: O20040729000452 |
News Archive
Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.
"Traction was introduced before it was properly evaluated in high-quality randomized trials, and as an intervention is already part of usual practice," said lead author Judy M.A. Clarke, M.D. "It is hard to convince health care providers not to use it."
In a paper to be published Nov. 22 in the online edition of the journal Science, a team of University of Wisconsin-Madison researchers reports the genetic reprogramming of human skin cells to create cells indistinguishable from embryonic stem cells.
Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.
› Verified 5 days ago
| Entity Name | Mississippi Emergency Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710220678 PECOS PAC ID: 2264672492 Enrollment ID: O20130710000827 |
News Archive
Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.
"Traction was introduced before it was properly evaluated in high-quality randomized trials, and as an intervention is already part of usual practice," said lead author Judy M.A. Clarke, M.D. "It is hard to convince health care providers not to use it."
In a paper to be published Nov. 22 in the online edition of the journal Science, a team of University of Wisconsin-Madison researchers reports the genetic reprogramming of human skin cells to create cells indistinguishable from embryonic stem cells.
Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.
› Verified 5 days ago
| Entity Name | Correct Care, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215987441 PECOS PAC ID: 8628980992 Enrollment ID: O20131122000662 |
News Archive
Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.
"Traction was introduced before it was properly evaluated in high-quality randomized trials, and as an intervention is already part of usual practice," said lead author Judy M.A. Clarke, M.D. "It is hard to convince health care providers not to use it."
In a paper to be published Nov. 22 in the online edition of the journal Science, a team of University of Wisconsin-Madison researchers reports the genetic reprogramming of human skin cells to create cells indistinguishable from embryonic stem cells.
Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.
› Verified 5 days ago
| Entity Name | Quality Medical Clinic, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720497936 PECOS PAC ID: 4688998172 Enrollment ID: O20150109000472 |
News Archive
Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.
"Traction was introduced before it was properly evaluated in high-quality randomized trials, and as an intervention is already part of usual practice," said lead author Judy M.A. Clarke, M.D. "It is hard to convince health care providers not to use it."
In a paper to be published Nov. 22 in the online edition of the journal Science, a team of University of Wisconsin-Madison researchers reports the genetic reprogramming of human skin cells to create cells indistinguishable from embryonic stem cells.
Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.
› Verified 5 days ago
| Entity Name | Yazoo Emergency Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447806914 PECOS PAC ID: 0749511574 Enrollment ID: O20191009002380 |
News Archive
Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.
"Traction was introduced before it was properly evaluated in high-quality randomized trials, and as an intervention is already part of usual practice," said lead author Judy M.A. Clarke, M.D. "It is hard to convince health care providers not to use it."
In a paper to be published Nov. 22 in the online edition of the journal Science, a team of University of Wisconsin-Madison researchers reports the genetic reprogramming of human skin cells to create cells indistinguishable from embryonic stem cells.
Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.
› Verified 5 days ago
| Entity Name | Delta Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215501788 PECOS PAC ID: 5890101208 Enrollment ID: O20210603000314 |
News Archive
Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.
"Traction was introduced before it was properly evaluated in high-quality randomized trials, and as an intervention is already part of usual practice," said lead author Judy M.A. Clarke, M.D. "It is hard to convince health care providers not to use it."
In a paper to be published Nov. 22 in the online edition of the journal Science, a team of University of Wisconsin-Madison researchers reports the genetic reprogramming of human skin cells to create cells indistinguishable from embryonic stem cells.
Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Harry G Hunt, MD 120 5th Ave, Mccomb, MS 39648-4159 Ph: (601) 249-0013 | Dr Harry G Hunt, MD 1212 Broad St, Columbia, MS 39429-3114 Ph: (601) 444-9266 |
News Archive
Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.
"Traction was introduced before it was properly evaluated in high-quality randomized trials, and as an intervention is already part of usual practice," said lead author Judy M.A. Clarke, M.D. "It is hard to convince health care providers not to use it."
In a paper to be published Nov. 22 in the online edition of the journal Science, a team of University of Wisconsin-Madison researchers reports the genetic reprogramming of human skin cells to create cells indistinguishable from embryonic stem cells.
Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.
› Verified 5 days ago
Dr. Jonathan Ryohwan Jang, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 W Lakeview Dr, Suite 2, Columbia, MS 39429 Phone: 601-444-4798 Fax: 601-444-5127 | |
Berthold Beisel, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 502 Broad St, Columbia, MS 39429 Phone: 601-736-8282 Fax: 601-736-8333 | |
Dr. Charles R. Griffith, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1560 Sumrall Rd, Columbia, MS 39429 Phone: 601-261-2940 Fax: 601-261-2942 | |
Terra Leigh Parker, Family Medicine Medicare: Medicare Enrolled Practice Location: 502 Broad St, Columbia, MS 39429 Phone: 601-736-8282 Fax: 601-579-5240 | |
Robert R Herrington Iii, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 502 Broad St, Columbia, MS 39429 Phone: 601-736-8282 Fax: 601-736-8533 | |
Dr. Stephen Marc Wascomb, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 554 Singley Rd, Columbia, MS 39429 Phone: 601-600-0036 |